
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Siglec-7 CRISPR/Cas9 KO Plasmid (h) | sc-407464 | 20 µg | $397.00 | |||
Siglec-7 HDR Plasmid (h) | sc-407464-HDR | 20 µg | $445.00 |
SIGLEC7 encodes Siglec-7, an inhibitory sialic acid–binding immunoglobulin-like lectin predominantly expressed on natural killer (NK) cells and subsets of myeloid cells. Through recognition of sialylated glycoconjugates and engagement of ITIM-dependent signaling, Siglec-7 recruits phosphatases such as SHP-1/2 to attenuate activating receptor pathways, shaping cytotoxicity and cytokine responses. This checkpoint-like regulation influences immune synapse formation, discrimination of self-associated glycans, and downstream modulation of MAPK and PI3K-linked signaling networks. Altered Siglec-7 expression or ligand density has been associated with immune evasion mechanisms in cancer and with dysregulated innate immune activation in inflammatory contexts, making it relevant for studies of tumor immunology and immune homeostasis.
Siglec-7 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SIGLEC7 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the SIGLEC7 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, Siglec-7 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined SIGLEC7 target site.
When co-transfected with Siglec-7 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the SIGLEC7 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.